Universal Ibogaine to Present at OTC Virtual Investor Event

2022-03-08T19:36:58-08:00March 8th, 2022|Uncategorized|

Universal Ibogaine Inc. to Webcast Live at OTC Markets VirtualInvestorConferences.com March 10th Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com Calgary, AB Canada, March 08, 2022 -- Universal Ibogaine (OTCQB:IBOGF TSXV:IBO FSE:JC4), a life sciences company based in Canada, focused on transforming the addiction treatment industry through the medical use of the [...]

UNIVERSAL IBOGAINE SIGNS MEMORANDUM OF UNDERSTANDING WITH OSOYOOS INDIAN BAND

2022-02-10T14:19:00-08:00February 10th, 2022|Uncategorized|

Calgary, AB – February 10, 2022 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”) a life sciences company with a mission to transform the world of addiction treatment through medicalized ibogaine and a state of the art ongoing care program, is pleased to advise it has entered a Memorandum of Understand (the “MOU”) with Osoyoos Indian Band Development Corporation [...]

UNIVERSAL IBOGAINE COMMENCES DEVELOPMENT PLAN AT KELBURN IN PREPARATION FOR IBOGAINE TREATMENTS AND PROVIDES UPDATE ON DRUG SUPPLY

2022-02-02T13:41:56-08:00February 2nd, 2022|Uncategorized|

CALGARY, AB, Feb. 2, 2022 /CNW/ - Universal Ibogaine Inc. (TSXV: IBO) ("UI" or the "Company") a life sciences company with a mission to deliver medicalized ibogaine-centered addiction treatment, has initiated development plans at its Kelburn treatment facility in preparation for treatment protocol approval and commencement of ibogaine treatments. What is Ibogaine? Ibogaine is a plant derived neuroactive compound that appears to reset [...]

UNIVERSAL IBOGAINE ENTERS DRUG SUPPLY AGREEMENT

2022-01-26T15:08:47-08:00January 26th, 2022|Uncategorized|

Calgary, AB – January 26, 2022 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”) a lifesciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, ispleased to advise it has entered into an agreement (the “agreement”) with Psygen Labs Inc. (“Psygen”)to secure a supply of GMP ibogaine for use in its planned future clinical trial for [...]

Universal Ibogaine Announces World-class Clinical Trial Partners in Advance of Clinical Trial Application For Ibogaine in Opioid Use Disorder

2022-01-14T09:00:00-08:00January 14th, 2022|Uncategorized|

Calgary, AB – January 14, 2022 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”) a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, is pleased to introduce its contract research organization (“CRO”) partners who will enable UI’s planned clinical trial in Canada to be conducted, subject to the required approval by Health Canada. [...]

Universal Ibogaine Announces Change in Leadership

2022-01-10T19:56:10-08:00January 10th, 2022|Uncategorized|

Calgary, AB - TheNewswire - January 10, 2022 - Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”) announces that Rami Batal has been replaced as Chief Executive Officer (“CEO”) of the Company and its subsidiaries.  For the present time, the Company has appointed Nick Karos as CEO, effective immediately.  Mr. Karos had recently been appointed as a Capital Markets consultant to the Company. [...]

Universal Ibogaine Announces Expansion of Executive Team and Grant of Stock Options

2021-12-22T22:04:06-08:00December 22nd, 2021|Uncategorized|

Calgary, AB - TheNewswire – December 2, 2021 – Universal Ibogaine Inc. (TSXV:IBO) (“ UI ” or the “ Company ”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, is pleased to announce an expansion of its’ Executive team, and welcomes Nick Karos as its new Director – Capital Markets. Mr. Karos is based in Los Angeles, USA, and [...]

Go to Top